Aim To determine if the association between hyperuricaemia and poor outcomes in heart failure (HF) varies by chronic kidney disease (CKD).Methods and resultsOf the 2645 systolic HF patients in the Beta-Blocker Evaluation of Survival Trial with data on baseline serum uric acid, 1422 had hyperuricaemia (uric acid 2). Hyperuricaemia-associated hazard ratios (HRs) and 95 confidence intervals (CI) for all-cause mortality and HF hospitalization were 1.44 (1.121.85, P 0.005) and 1.27 (1.021.58, P 0.031), respectively. Hazard ratios (95 CIs) for all-cause mortality among those with and without CKD were 0.96 (0.701.31, P 0.792) and 1.40 (1.081.82, P 0.011), respectively (P for interaction, 0.071), and those for HF hospitalization among those with and without CKD were 0.99 (0.741.33, P 0.942) and 1.49 (1.191.86, P 0.001), respectively (P for interaction, 0.033).Conclusion Hyperuricaemia has a significant association with poor outcomes in HF patients without CKD but not in those with CKD, suggesting that hyperuricaemia may predict poor outcomes when it is primarily a marker of increased xanthine oxidase activity, but not when it is primarily due to impaired renal excretion of uric acid.
- Chronic kidney disease
- Heart failure
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine